Bayer stock fell 1.08 percent as Q2 growth met its next test

Published on 10/07/2026 at 14:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock's Q2 report showed EUR 10.872 billion in sales and EUR 2.144 billion EBITDA before special items. Q3 results are scheduled for November 3, 2026.

Architekturfotografie: modernes Pharma-Forschungsgebäude mit Vorhangfassade aus Stahl und Glas, aufgenommen von unten mit starker perspektivischer Linienführung bei bedecktem Himmel — Moderne Pharma-Campus-Fassade aus Stahl und Glas, Froschperspektive, Illustration mit AI erstellt.

Bayer stock (ISIN DE000BAY0017) fell 1.08 percent to EUR 43.96 on Xetra on October 7, 2026, at 2:01 p.m. CEST. The move came as investors weighed positive Q2 operating figures against cautious expectations for the next agricultural update.

Q2 sales rose 2.2 percent

According to Bayer, group sales in Q2 2026 increased 2.2 percent on a currency and portfolio adjusted basis to EUR 10.872 billion. EBITDA before special items rose 1.9 percent to EUR 2.144 billion, while core earnings per share increased 16.7 percent.

The underlying picture is therefore better than the share-price session suggests. Bayer's latest investor material covers Crop Science, Pharmaceuticals and Consumer Health, leaving the third-quarter report to show whether the agricultural recovery can offset legal and financing pressure.

November results set the next test

Bayer's Q3 2026 results are scheduled for November 3, 2026, according to the company's quarterly reports page. That date gives investors a defined checkpoint after the Q2 revenue increase and the 1.9 percent EBITDA improvement.

JPMorgan kept Bayer at Overweight with a EUR 61 price target in its October 1, 2026 note, according to Finanznachrichten. Analyst Richard Vosser said early Q3 expectations appeared too high because of timing effects in Crop Science, while full-year estimates were largely unchanged.

The broader consensus remains above the market quote. MarketScreener lists 18 analysts, an Outperform consensus and an average target of EUR 58.22. That target is 32.4 percent above the Xetra price of EUR 43.96, a gap that makes the November figures especially important for the valuation debate.

Bayer stock stays below its yearly high

At EUR 43.96, Bayer stock was 18.5 percent below its 52-week high of EUR 53.92 and 70.5 percent above its 52-week low of EUR 25.78 on October 7, 2026. The market capitalization was EUR 43.2 billion and trading volume reached 711,566 shares.